BR0109455A - Uso de mia e/ou seus fragmentos, método para tratar mamìferos sofrendo de, ou susceptìvel a, uma doença inflamatória, peptìdeo, composição farmacêutica, e, uso dos peptìdeos - Google Patents

Uso de mia e/ou seus fragmentos, método para tratar mamìferos sofrendo de, ou susceptìvel a, uma doença inflamatória, peptìdeo, composição farmacêutica, e, uso dos peptìdeos

Info

Publication number
BR0109455A
BR0109455A BR0109455-6A BR0109455A BR0109455A BR 0109455 A BR0109455 A BR 0109455A BR 0109455 A BR0109455 A BR 0109455A BR 0109455 A BR0109455 A BR 0109455A
Authority
BR
Brazil
Prior art keywords
mia
peptides
fragments
peptide
pharmaceutical composition
Prior art date
Application number
BR0109455-6A
Other languages
English (en)
Inventor
Robert Louis Hubert Nelissen
Gijsbertus Francisc Verheijden
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR0109455A publication Critical patent/BR0109455A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"USO DE MIA E/OU SEUS FRAGMENTOS, MéTODO PARA TRATAR MAMìFEROS SOFRENDO DE, OU SUSCEPTìVEL A, UMA DOENçA INFLAMATóRIA, PEPTìDEO, COMPOSIçãO FARMACêUTICA, E, USO DOS PEPTìDEOS". A invenção refere-se ao uso de MIA para prevenir doenças inflamatórias e, em particular, a seu uso no tratamento de destruição crónica da cartilagem articular. Mais especificamente, MIA pode ser usada para induzir tolerância específica de célula-T ao antígeno MIA em pacientes sofrendo de artrite reumatóide.
BR0109455-6A 2000-03-23 2001-03-15 Uso de mia e/ou seus fragmentos, método para tratar mamìferos sofrendo de, ou susceptìvel a, uma doença inflamatória, peptìdeo, composição farmacêutica, e, uso dos peptìdeos BR0109455A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00201063 2000-03-23
PCT/EP2001/002991 WO2001070253A1 (en) 2000-03-23 2001-03-15 Use of mia in immunotherapy

Publications (1)

Publication Number Publication Date
BR0109455A true BR0109455A (pt) 2003-06-03

Family

ID=8171248

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109455-6A BR0109455A (pt) 2000-03-23 2001-03-15 Uso de mia e/ou seus fragmentos, método para tratar mamìferos sofrendo de, ou susceptìvel a, uma doença inflamatória, peptìdeo, composição farmacêutica, e, uso dos peptìdeos

Country Status (19)

Country Link
US (1) US20030091583A1 (pt)
EP (1) EP1267907A1 (pt)
JP (1) JP2003527435A (pt)
KR (1) KR20020089404A (pt)
CN (1) CN1418105A (pt)
AR (1) AR027694A1 (pt)
AU (1) AU783170B2 (pt)
BR (1) BR0109455A (pt)
CA (1) CA2399028A1 (pt)
CZ (1) CZ20023187A3 (pt)
HU (1) HUP0300997A2 (pt)
IL (1) IL150679A0 (pt)
MX (1) MXPA02008889A (pt)
NO (1) NO20024458D0 (pt)
NZ (1) NZ520346A (pt)
PL (1) PL358132A1 (pt)
RU (1) RU2002128351A (pt)
SK (1) SK13692002A3 (pt)
WO (1) WO2001070253A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076965A1 (en) * 2002-10-16 2004-04-22 Bosserhoff Anja Katrin MIA-2 protein
US8026354B2 (en) * 2005-11-23 2011-09-27 Institut Pasteur Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use
WO2007120947A1 (en) * 2006-01-13 2007-10-25 Indiana University Research & Technology Corporation Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung
JP5984388B2 (ja) * 2008-07-16 2016-09-06 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン
SG10201502398RA (en) 2010-04-27 2015-05-28 Scil Technology Gmbh Stable MIA/CD-RAP formulations
ITRM20110134A1 (it) * 2011-03-22 2012-09-23 Matteo Bordignon Inibitori di mia (attività inibitoria melanoma) per identificare, prevenire e curare la vitiligine
CA2868123A1 (en) * 2012-03-23 2013-09-26 The University Of Queensland Immunomodulatory agent and uses therefor
ITRM20120339A1 (it) * 2012-07-16 2014-01-17 Matteo Bordignon Uso di mia (attività inibitoria melanoma) per il trattamento della iper-pigmentazione cutanea e per lo sbiancamento cosmetico della pelle
CN116327971A (zh) * 2023-03-02 2023-06-27 暨南大学附属第一医院（广州华侨医院） 一种靶向cd74+促炎型巨噬细胞的药物载体及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770366A (en) * 1993-07-20 1998-06-23 Boehringer Mannheim Gmbh Melanoma-inhibiting protein
JP2001509029A (ja) * 1997-01-21 2001-07-10 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒトタンパク質
EP0909954B1 (de) * 1997-10-16 2003-11-26 Scil Technology Holding GmbH Nachweis von Knorpelerkrankungen mit MIA

Also Published As

Publication number Publication date
JP2003527435A (ja) 2003-09-16
CN1418105A (zh) 2003-05-14
NO20024458L (no) 2002-09-18
HUP0300997A2 (hu) 2003-07-28
CZ20023187A3 (cs) 2003-01-15
IL150679A0 (en) 2003-02-12
KR20020089404A (ko) 2002-11-29
US20030091583A1 (en) 2003-05-15
NO20024458D0 (no) 2002-09-18
WO2001070253A8 (en) 2003-03-20
RU2002128351A (ru) 2004-03-27
MXPA02008889A (es) 2003-04-25
WO2001070253A1 (en) 2001-09-27
AU783170B2 (en) 2005-09-29
SK13692002A3 (sk) 2003-02-04
CA2399028A1 (en) 2001-09-27
AR027694A1 (es) 2003-04-09
NZ520346A (en) 2004-07-30
AU4247601A (en) 2001-10-03
EP1267907A1 (en) 2003-01-02
PL358132A1 (en) 2004-08-09

Similar Documents

Publication Publication Date Title
Murata et al. Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery
PT942740E (pt) Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf
Leipner et al. Therapy with proteolytic enzymes in rheumatic disorders
CY1118849T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
TR200101205T1 (tr) ímmn hastalìklarìn tedavisi i‡in bir farmas”tik terkip
BR0008276A (pt) Combinações de formoterol e propionato de fluticasona para asma
BR9811556A (pt) Terapia de combinação compreendendo atorvastatina e um agente anti-hipertensivo
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
BR9809951A (pt) Método para tratamento da obesidade
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
SE9800550D0 (sv) A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
BR0109455A (pt) Uso de mia e/ou seus fragmentos, método para tratar mamìferos sofrendo de, ou susceptìvel a, uma doença inflamatória, peptìdeo, composição farmacêutica, e, uso dos peptìdeos
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
BR0313239A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças
EP0957925A4 (en) TREATMENT OF OSTEOARTHRITIS BY ADMINISTRATION OF POLY-N-ACETYL-D-GLUCOSAMINE
DK0624374T3 (da) Anvendelse af sulodexid og medicin, som indeholder dette, til behandlingen af diabetisk nephropati
CA2294090C (en) Method and product using sturgeon notochord for alleviating the symptoms of arthritis
SE9603725D0 (sv) New teatment
Tanaka et al. Suppressive effects of hyaluronan on MMP-1 and RANTES production from chondrocytes
BR0012942A (pt) Aplicação de flupirtin para a diminuição de dores em doenças articulares degenerativas de cães e gatos
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
BR0113646A (pt) Tratamento de distúrbios inflamatórios
BR9808866A (pt) Moléculas retinóicas relacionadas à inibição da superprodução de endotelina-1 em doenças
BR9912378A (pt) Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição para diagnóstico.
Manjhi et al. Effects of Balsamodendron mukul gum resin extract on articular cartilage in papain-induced osteoarthritis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., 7A., E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO DA RPI 2016 DE 25/08/2009.